Recombinant MVA Virus with Restructured Insertion Sites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant modified vaccinia Ankara (MVA) viruses experience instability in maintaining heterologous DNA sequences, leading to loss of foreign gene expression and growth disadvantage, which complicates vaccine production and stability.
Innovation Solution
Restructuring regions of the MVA genome by removing non-essential DNA and making essential genes adjacent, creating stable insertion sites between essential open reading frames for heterologous nucleic acid sequences, ensuring their maintenance in the virus population.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If heterologous DNA sequences are inserted into the MVA genome, then foreign gene expression is achieved, but genetic stability is lost leading to deletion of inserted sequences
Solution Approach 1:
The patent removes non-essential DNA sequences from the MVA genome to create streamlined insertion sites. By extracting and eliminating unnecessary genetic material, the patent creates a more stable genomic structure that prevents deletion of heterologous DNA while maintaining essential viral functions. This extraction principle directly addresses the instability problem by simplifying the genomic architecture around insertion sites.
Solution Approach 2:
The patent performs preliminary restructuring of the MVA genome before inserting heterologous DNA sequences. By pre-organizing the genomic structure, removing non-essential sequences, and creating optimized insertion sites in advance, the patent ensures that subsequent heterologous DNA insertions remain stable. This preliminary action prevents future deletion events by establishing a robust genomic framework beforehand.
2Device complexity
If non-essential DNA is retained in the MVA genome, then genome complexity is maintained, but stability of heterologous DNA insertion is reduced
Solution Approach 1:
The patent systematically extracts and removes non-essential DNA sequences from the MVA genome. This extraction process eliminates genetic elements that contribute to instability without removing sequences necessary for viral replication and function. The result is a simplified genome structure with enhanced stability for heterologous DNA maintenance.
Solution Approach 2:
The patent applies local quality changes by creating specific, optimized insertion sites with particular structural characteristics. Rather than uniformly simplifying the entire genome, the patent focuses local restructuring efforts on specific regions where heterologous DNA will be inserted. This localized approach maintains necessary genome complexity in essential regions while creating stable, simplified structures at insertion sites.
3Adaptability or versatility
If essential genes are made adjacent in the MVA genome, then insertion sites are created for heterologous DNA, but genome restructuring complexity increases
Solution Approach 1:
The patent segments the MVA genome into functional regions, identifying and separating essential genes from non-essential sequences. By dividing the genome into distinct functional segments, the patent can reorganize essential genes into adjacent positions to create insertion sites without disrupting overall viral function. This segmentation facilitates systematic restructuring while maintaining genomic integrity.
Solution Approach 2:
The patent merges adjacent essential genes into contiguous arrangements to create stable insertion sites. By combining or placing essential genes next to each other, the patent generates defined genomic regions suitable for heterologous DNA insertion. This merging approach simplifies the genome structure in specific regions while providing versatile insertion opportunities.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.